Pfizer buys vaccine company PowderMed in all-cash deal
In its first foray into vaccines, Pfizer is acquiring DNA vaccine company PowderMed for about $200mm in cash, with an additional estimated $20-30mm payable on achieving a clinical milestone.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.